Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer—a review

References

• Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009, 9, 550–562.
   PubMed Web of Science ®Google Scholar
• Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007, 6, 115–120.
   PubMed Web of Science ®Google Scholar
• Rebecca J, Lingwood Boyle, P, Milburn A, Ngoma T, Arbuthnott J, Mc-caffrey R, Kerr HS, Kerr JD. Science and Society, The challenge of cancer control in Africa. Nat Rev Cancer 2008, 8, 398–403.
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer 2008, 8, 473–480.
   PubMed Web of Science ®Google Scholar
• Samad A, Dua K, Sarma P, Prajapathi. Biomarkers: A Novel Approach for Targeted Cancer Therapy. Pharmainfo.net, Latest Reviews http://www.pharmainfo.net/reviews/biomarkers-novel-approach-targeted-cancer-therapy (Accessed 6 April 2008).
   Google Scholar
• Cunningham AP, Love WK, Zhang RW, Andrews LG, Tollefsbol  TO. Telomerase inhibition in cancer therapeutics: molecular-based approaches. Curr Med Chem 2006, 13, 2875–2888.
   PubMed Web of Science ®Google Scholar
• Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, Smith  PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998, 58, 5009–5013.
   PubMed Web of Science ®Google Scholar
• Jennifer BL, Brian RC. Duplication of the genome in normal and cancer cell cycles. Cancer Biol Ther 2002, 1, 8–13.
   PubMed Web of Science ®Google Scholar
• Jain KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin Pharmacother 2005, 6, 1463–1476.
   PubMed Web of Science ®Google Scholar
• Scinski P, Deshpande A, Hinds WP. Cyclins CDKS in development and cancer: a perspective. Oncogene 2005, 24, 2909–2915.
   PubMed Web of Science ®Google Scholar
• Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999, 287, 821–828.
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989, 246, 629–634.
   PubMed Web of Science ®Google Scholar
• John PC, Mews M, Moore R. Cyclin/Cdk complexes: their involvement in cell cycle progression and mitotic division. Protoplasma 2001, 216, 119–42.
   PubMed Web of Science ®Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1, 222–231.
   PubMed Web of Science ®Google Scholar
• Morgan DO. Principles of CDK regulation. Nature 2002, 374, 131–134.
   Google Scholar
• Morgan DO. The cell cycle: principles of control. New Science Press 2007, 273–297.
   Google Scholar
• D’Andrilli G, Kumar C, Scambia G, Giordano A. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 2004, 10, 8132–8141.
   PubMed Web of Science ®Google Scholar
• Morgan DO. Cyclin - dependent kinases. Engines, clocks and microprocessors. Annu Rev Cell Dev Biol 1997, 1, 261–291.
   Google Scholar
• Major S, Endicott J. Structural biology of cell cycle proteins. Drug Dis Today Targets 2004, 3, 136–142.
   Google Scholar
• Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009, 9, 153–166.
   PubMed Web of Science ®Google Scholar
• Helmut B, Clarissa G. Molecular mechanisms of cancer induction and chemoprevention. In: Siegfried K, David MDeM, Johnson  I, Clarissa G. Chemoprevention of Cancer and DNA Damage by Dietary Factors. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2009, 3–20.
   Google Scholar
• Luh SP, Moulay AAJ. New targets, new agents and the evolving phenomenon of drug resistance in cancer. Cur Cancer Ther Rev 2006, 2, 23–30.
   Google Scholar
• Miguel HB, Foote AM, Giaccone G, Olopade O, Workman P. Selecting the Right Targets for Cancer Therapy, Principles of Molecular Oncology. 3rd edn. Totowa, NJ, Humana press Inc., 2008, 1–26.
   Google Scholar
• Specenier PM, Vermorken JB. Recurrent head and neck cancer current treatment and future prospects. Expert Rev of Anti Cancer Ther 2006, 8, 375–391.
   Web of Science ®Google Scholar
• Desany B, Zhang Z. Bioinformatics and cancer target discovery. Drug Discov Today 2004, 9, 795–802.
   PubMed Web of Science ®Google Scholar
• Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, Vierfond JM, Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 2003, 46, 222–236.
   PubMed Web of Science ®Google Scholar
• Katona RL, Lahtl JM, Cyclin C. Genetics and Tumour Cell Biology. UCSD - Nature Molecule Pages. http://www.signaling-gateway.org/molecule/query?afcsid=A000720. Published online: 28 Feb 2006 | DOI:10.1038/mp.a000720.01.
   Google Scholar
• Tassan JP, Jaquenoud M, Léopold P, Schultz SJ, Nigg EA. Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. Proc Natl Acad Sci USA 1995, 92, 8871–8875.
   PubMed Web of Science ®Google Scholar
• Gold MO, Tassan JP, Nigg EA, Rice AP, Herrmann CH. Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8. Nucleic Acids Res 1996, 24, 3771–3777.
   PubMed Web of Science ®Google Scholar
• Rickert P, Seghezzi W, Shanahan F, Cho H, Lees E. Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. Oncogene 1996, 12, 2631–2640.
   PubMed Web of Science ®Google Scholar
• Kang ME, Dahmus ME. RNA polymerases IIA and IIO have distinct roles during transcription from the TATA-less murine dihydrofolate reductase promoter. J Biol Chem 1993, 268, 25033–25040.
   PubMed Web of Science ®Google Scholar
• Aseem ZA, Anuja O, Mark P. Transcriptional activating regions target attached substrates to a cyclin-dependent kinase. PNAS 2005, 102, 2346–2349.
   PubMed Web of Science ®Google Scholar
• Ana T, Branka J, Mary S. Yeast Gal4: a transcriptional paradigm revisited. EMBO reports 2006, 7, 496–499.
   PubMed Web of Science ®Google Scholar
• Shiekhattar R, Mermelstein F, Fisher RP, Drapkin R, Dynlacht  B, Wessling HC, Morgan DO, Reinberg D. Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature 1995, 374, 283–287.
   PubMed Web of Science ®Google Scholar
• Akoulitchev S, Chuikov S, Reinberg D. TFIIH is negatively regulated by cdk8-containing mediator complexes. Nature 2000, 407, 102–106.
   PubMed Web of Science ®Google Scholar
• Hengartner CJ, Myer VE, Liao SM, Wilson CJ, Koh SS, Young RA. Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases. Mol Cell 1998, 2, 43–53.
   PubMed Web of Science ®Google Scholar
• Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004, 117, 239–251.
   PubMed Web of Science ®Google Scholar
• Tomashevski A, Webster DR, Grammas P, Gorospe M, Kruman II. Cyclin-C-dependent cell-cycle entry is required for activation of non-homologous end joining DNA repair in postmitotic neurons. Cell Death Differ 2010, 1–10. DOI: 10.1038/cdd.2009.221.
   PubMed Web of Science ®Google Scholar
• Sage J. Cyclin C makes an entry into the cell cycle. Dev Cell 2004, 6, 607–608.
   PubMed Web of Science ®Google Scholar
• Büschges R, Weber GR, Actor B, Lichter P, Collins PV, Reifenberger G. Amplification and expression of cyclin D genes (CCND1 CCND2 and CCND3) in human malignant gliomas. Brain Path 1999, 9, 442–435.
   Web of Science ®Google Scholar
• Dowdy SF, Hinds PW, Louie K, Reed SI, Arnold A, Weinberg RA. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993, 73, 499–511.
   PubMed Web of Science ®Google Scholar
• Coqueret O. Linking cyclins to transcriptional control. Gene 2002, 299, 35–55.
   PubMed Web of Science ®Google Scholar
• Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, Howley PM. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996, 93, 4350–4354.
   PubMed Web of Science ®Google Scholar
• Erik KF, Samuel HS, William GKJRt. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci Biochemistry 1993, 90, 6914–6918.
   PubMed Web of Science ®Google Scholar
• Daya PJ, Cleasbya A, Ticklea IJ, O’Reillya M, Coylea JE, Holdinga  FP, McMenamina RL, Yona J, Choprab R, Lengauerc C, Harren J. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci 2009, 106, 4166–4170.
   PubMed Web of Science ®Google Scholar
• Jui-Wen H, Chung-Wai S, Ya-Ting Y, Samuel KK, Kuen - Feng C, Robert BW, Charles SL, Ching-Shih C. Peroxisome proliferators - activated receptor γ - independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharm 2005, 67, 1342–1348.
   Web of Science ®Google Scholar
• Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest 2008, 118, 1750–1764.
   PubMed Web of Science ®Google Scholar
• Kovalsky O, Lung FD, Roller PP, Fornace AJ Jr. Oligomerization of human Gadd45a protein. J Biol Chem 2001, 276, 39330–39339.
   PubMed Web of Science ®Google Scholar
• Hollander MC, Philburn RT, Patterson AD, Wyatt MA, Fornace  AJ Jr. Genomic instability in Gadd45a-/- cells is coupled with S-phase checkpoint defects. Cell Cycle 2005, 4, 704–709.
   PubMed Web of Science ®Google Scholar
• Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O’Connor PM, Fornace AJ Jr. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994, 266, 1376–1380.
   PubMed Web of Science ®Google Scholar
• Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, Schulz WA, Singal R. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res 2009, 69, 1527–1535.
   PubMed Web of Science ®Google Scholar
• Barreto G, Schäfer A, Marhold J, Stach D, Swaminathan SK, Handa V, Döderlein G, Maltry N, Wu W, Lyko F, Niehrs C. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007, 445, 671–675.
   PubMed Web of Science ®Google Scholar
• Larson SP,Benjamin LS,Chia - Lin K,Yang Q,Glass NC,Pistey RMC,Morenas A,Rosenberg LC. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. B M C Cancer 2008, 8, 68.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002, 21, 2741–2749.
   PubMed Web of Science ®Google Scholar
• Ioannis PS, Kalliopi A, Marilena K, Kosta E, Petros T, Triantafilos L, Giorgos N, Fragiska S, Christos K, John FK, Athanassios K, Vassilis GG. Downregulation of the KIP family members p27KIP1 and p57KIP2 by SKP2 and the role of methylation in p57KIP2 inactivation in non small cell lung cancer. Intl J Cancer 2006, 119, 2546–2556.
   PubMed Web of Science ®Google Scholar
• Yang X, Karuturi RKM, Sun F, Aau M, Yu K, Shao R, Miller DL, Tan BOP, Yu Q. CDKN1C (p57KIP2) is a direct Target of EZH2 and Suppressed by Multiple Epigenetic Mechanisms in Breast Cancer Cells. PLoS ONE. http://www.plosone.org/article/info:doi/10.1371/journal.pone.0005011. PLoS One 2009, 4(4): e5011. Epub 2009 Apr 2.
   Google Scholar
• Zeng H, Wu M, Botnen JH. Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase ½ pathway and other cancer signaling genes. J Nutr 2009, 139, 1613–1618.
   PubMed Web of Science ®Google Scholar
• Hait WN, Hambley TW. Targeted cancer therapeutics. Cancer Res 2009, 69, 1263–7; discussion 1267.
   PubMed Web of Science ®Google Scholar
• Lui CM, Marshal JL, Pestell RG. Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. Curr Cancer Drug Ther 2004, 4, 403–424.
   PubMed Web of Science ®Google Scholar
• Ah-Song R, Sasco AJ. Tamoxifen and ocular toxicity. Cancer Detect Prev 1997, 21, 522–531.
   PubMedGoogle Scholar
• Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004, 25, 1711–1720.
   PubMed Web of Science ®Google Scholar
• Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells. Oncogene 2003, 22, 8271–8282.
   PubMed Web of Science ®Google Scholar
• Zehan C, Zhan X, Gu W-Z Xue, J, Bui MH, Kovar P, Gaoquan  L, Wang G, Tao Z-F Yunsong, T, Lin N-H Sham, HL, Wang JYJ, Sowin  TJ, Rosenberg SH, Haiying Z. Selective CHK-1 inhibitors differentially sensitise P-53 deficient cancer cells. Intl J Cancer 2006, 119, 2784–2794.
   PubMed Web of Science ®Google Scholar
• Kathy W. Liposomal doxorubicin. CJON 2002, 6, 59–61.
   Google Scholar
• McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva  D, Lane DP. In vivo and vitro anti-tumour properties of the cyclin dependent kinase inhibitor CYC202 (R - roscovitine). Intl J Cancer 2002, 102, 463–468.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe  M, Akinaga S. G1phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor P21/ cip 1 / WAF1/ sdi 1 in p53 mutated human epidermoid carcinoma A431cells. Cancer Res 1997, 576, 1495–1501.
   Google Scholar
• Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O’Connor PM. UCN-01, a potent abrogator of G2 check point function in cancer cells with disrupted p53. J Natl Cancer Instit 1996, 88, 956–965.
   PubMed Web of Science ®Google Scholar
• Fiona McL, Paul F, Nicholas BLT. The cell cycle, chromatin and cancer: mechanism-based therapeutics comes of age. DDT 2003, 8, 793–802.
   Google Scholar
• Honma T, Yoshizumi T, Hashimoto N, Hayashi K, Kawanishi N, Fukasawa K, Takaki T, Ikeura C, Ikuta M, Suzuki-Takahashi I, Hayama T, Nishimura S, Morishima H. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues. J Med Chem 2001, 44, 4628–4640.
   PubMed Web of Science ®Google Scholar
• Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo  WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, Jain A, Collins  C, Nishizuka S, Tonon G, Roschke A, Gehlhaus K, Kirsch I, Scudiero DA, Gray JW, Weinstein JN. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006, 5, 853–867.
   PubMed Web of Science ®Google Scholar
• Kontopidis G, Andrews MJ, McInnes C, Plater A, Innes L, Renachowski S, Cowan A, Fischer PM. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design. Chem Med Chem 2009, 4, 1120–1128.
   Google Scholar